BD Rolls Out New Method to Automate, Standardize Single-Cell Research

BD (Becton, Dickinson and Company) has launched the first in a family of high-throughput, robotics-compatible reagent kits that enables automation to ensure greater consistency and increased efficiency of large-scale, single-cell discovery studies.

The automated solution from the BD and Hamilton collaboration standardizes traditionally manual processes and speeds the generation of material for genetic sequencing. The solution includes the newly-released BD OMICS-One XT WTA Assay and the Hamilton Microlab NGS STAR automated liquid handling platform. Since the NGS STAR is already installed in many laboratories and facilities worldwide, more researchers processing samples across an array of genomics applications can easily integrate the new automation-ready BD assay into existing workflows.

“By automating the complex library preparation process, researchers can scale their sample throughput and expect more consistent results, minimizing the variability introduced by manual procedures,” BD Biosciences Worldwide President Steve Conly said. “This standardization is crucial for the reproducibility of experiments, which is a cornerstone of scientific research. The integration of Hamilton’s robotics with BD’s robotics-ready reagent kits can streamline workflows, reduce the potential for human error, and accelerate the pace of discovery in critical areas such as oncology and immunology.”

In single-cell discovery studies involving genetic material, constructing preparatory material otherwise called “DNA libraries” is an essential early step. Historically, such preparations have been labor-intensive and time-consuming processes, with numerous manual steps that often lead to variability of results, compromised data quality, limited throughput, high cost and long turnaround times.

“Hamilton’s advanced automated solutions streamline scientific workflows, maximizing the potential of single-cell multiomics research,” Hamilton CEO Matt Hamilton stated. “Our partnership with BD furthers our mission to provide innovative technologies that accelerate groundbreaking discoveries in science and medicine.”

The BD OMICS-One XT Library Preparation Reagent Kits and Hamilton Microlab NGS STAR automated liquid handling platform and applications are commercially available globally.

BD is one of the world’s largest global medical technology companies and advances health by improving medical discovery, diagnostics, and care delivery. The company develops technology, services, and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its more than 70,000 employees help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease, and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations globally to address challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.